Parkinson’s disease and osteoporosis: basic and clinical implications

References

• Kinsella K, Wan H. U.S. Aging World: 2008. Washington (DC): An, U.S. Government Printing Office; 2009. (Census Bureau, International Population Reports, P95/09-1).
   Google Scholar
• Hiorth Y, Lode K, Larsen JP. Frequencies of falls and associated features at different stages of Parkinson’s disease. Eur J Neurol. 2013;20:160–166.
   PubMed Web of Science ®Google Scholar
• Jankovic J. Parkinson’s disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008;79:368–376.
   PubMed Web of Science ®Google Scholar
• Chen H, Zhang S, Hernan M, et al. Weight loss in Parkinson’s disease. Ann Neurol. 2003;53:676–679.
   PubMed Web of Science ®Google Scholar
• Pouwels S, Bazelier MT, Boer A, et al. Risk of fracture in patients with Parkinson’s disease. Osteoporos Int. 2013;24:2283–2290.
   PubMed Web of Science ®Google Scholar
• Spillantini M, Schmidt M, Lee V, et al. α-synuclein in lewy bodies. Nature. 1997;388:839–840.
   PubMed Web of Science ®Google Scholar
• Maroteaux L, Campanelli JT, Scheller R. Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J Neurosci. 1988;8:2804–2815.
   PubMed Web of Science ®Google Scholar
• Tredici K, Braak H. Idiopathic Parkinson’s disease: staging an α-synucleinopathy with a predictable pathoanatomy. Madame Curie Bioscience Database. Austin (TX): Landes Bioscience; 2000–2013.
   Google Scholar
• Claassen DO, Josephs KA, Ahlskog JE, et al. REM sleep behavior disorder preceding other aspects of synucleinopathies by up to half a century. Neurology. 2010;75:494–499.
   PubMed Web of Science ®Google Scholar
• Shen Y, Liu CF. Sleep disorders in Parkinson’s disease: present status and future prospect. Chin Med J (Engl). 2018;131:883–885.
   PubMed Web of Science ®Google Scholar
• Maiga B, Diop MS, Sangare M, et al. Sleep quality assessment in 35 Parkinson’s disease patients in the fann teaching hospital, Dakar, Senegal. Rev Neurol (Paris). 2016;172:242–247.
   PubMed Web of Science ®Google Scholar
• Niccolini F, Wilson H, Giordano B, et al. Sleep disturbances and gastrointestinal dysfunction are associated with thalamic atrophy in Parkinson’s disease. BMC Neurosci. 2009;22(20(1)):55.
   Google Scholar
• Niwa F, Kuriyama N, Nakagawa M, et al. Circadian rhythm of rest activity and autonomic nervous system activity at different stages in Parkinson’s disease. Auton Neurosci. 2011;165:195–200.
   PubMed Web of Science ®Google Scholar
• Jellinger K. Neuropathobiology of non-motor symptoms in Parkinson disease. J Neural Transm. 2015;122:1429–1440.
   PubMed Web of Science ®Google Scholar
• Stiasny-Kolster K, Doerr Y, Möller JC, et al. Combination of ‘idiopathic’ REM sleep behaviour disorder and olfactory dysfunction as possible indicator for alpha-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT. Brain. 2005;128:126–137.
   PubMed Web of Science ®Google Scholar
• Edwards LL, Quigley EM, Pfeiffer RF. Gastrointestinal dysfunction in Parkinson’s disease: frequency and pathophysiology. Neurology. 1992;42:726–732.
   PubMed Web of Science ®Google Scholar
• Lebouvier T, Chaumette T, Damier P, et al. Pathological lesions in colonic biopsies during Parkinson’s disease. Gut. 2008;57(12):1741–1743.
   PubMed Web of Science ®Google Scholar
• Senard JM, Raï S, Lapeyre-Mestre M, et al. Prevalence of orthostatic hypotension in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1997;63(5):584–589.
   PubMed Web of Science ®Google Scholar
• Magerkurth C, Schnitzer R, Braune S. Symptoms of autonomic failure in Parkinson’s disease: prevalence and impact on daily life. Clin Auton Res. 2015;15:76–82.
   Google Scholar
• Kim HJ, Oh ES, Lee JH, et al. Relationship between changes of body mass index (BMI) and cognitive decline in Parkinson’s disease (PD). Arch Gerontol Geriatr. 2012;55:70–72.
   PubMed Web of Science ®Google Scholar
• Akbar U, He Y, Dai Y, et al. Weight loss and impact on quality of life in Parkinson’s disease. PLoS ONE. 2015;10(5):e0124541.
   PubMed Web of Science ®Google Scholar
• Gao H, Wei X, Liao J, et al. Lower bone mineral density in patients with Parkinson’s disease: a cross-sectional study from Chinese Mainland. Front Aging Neurosci. 2015;7:203.
   PubMed Web of Science ®Google Scholar
• Tandberg E, Larsen JP, Aarsland D, et al. The occurrence of depression in Parkinson’s disease. A community-based study. Arch Neurol. 1996;53:175–179.
   PubMed Web of Science ®Google Scholar
• Marinus J, Leentjens A, Visser M, et al. Evaluation of the hospital anxiety and depression scale in patients with Parkinson’s disease. Clin Neuropharmacol. 2002;25:318–324.
   PubMed Web of Science ®Google Scholar
• Papapetropoulos S. Factors associated with drug–induced visual hallucinations in Parkinson’s disease. J Neurol. 2005;252:1223–1228.
   PubMed Web of Science ®Google Scholar
• Weintraub D, Koester J, Potenza MN, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol. 2010;67:589–595.
   PubMed Web of Science ®Google Scholar
• Zhang G, Zhang Z, Liu L, et al. Impulsive and Compulsive Behaviors in Parkinson’s Disease. Front Aging Neurosci. 2014;6:318.
   PubMed Web of Science ®Google Scholar
• Kanis JA, Black D, Cooper C, et al. A new approach to the development of assessment guidelines for osteoporosis. Osteoporos Int. 2002;13:527–536.
   PubMed Web of Science ®Google Scholar
• Johnell O, Gullberg B, Kanis JA. The hospital burden of vertebral fracture in Europe: a study of national register sources. Osteoporos Int. 1997;7:138–144.
   PubMed Web of Science ®Google Scholar
• Taggard H, Crawford V. Reduced bone density of the hip in elderly patients with Parkinson’s disease. Age Ageing. 1995;24:326–328.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Shen L, Ji HF. Osteoporosis risk and bone mineral density levels in patients with Parkinson’s disease: a meta-analysis. Bone. 2013;52:498–505.
   PubMed Web of Science ®Google Scholar
• Hagenau T, Vest R, Gissel TN, et al. Global vitamin D levels in relation to age, gender, skin pigmentation and latitude: an ecologic meta-regression analysis. Osteoporos Int. 2009;20:133–140.
   PubMed Web of Science ®Google Scholar
• Karsenty G. Convergence between bone and energy homeostasis: leptin regulation of bone mass. Cell Metab. 2006;4(5):341–348.
   PubMed Web of Science ®Google Scholar
• Glass DA, Bialek P, Ahn JD, et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell. 2005;8:751–764.
   PubMed Web of Science ®Google Scholar
• Kondo A, Togari A. In vivo stimulation of sympathetic nervous system modulates osteoblastic activity in mouse calvaria. Am J Physiol Endocrinol Metab. 2003;285:E661–7.
   PubMed Web of Science ®Google Scholar
• Webber RH, DeFelice R, Ferguson RJ, et al. Bone marrow response to stimulation of the sympathetic trunks in rats. Acta Anat (Basel). 1970;77:92–97.
   PubMedGoogle Scholar
• Asada N, Katayama Y, Sato M, et al. Matrix-embedded osteocytes regulate mobilization of hematopoietic stem/progenitor cells. Cell Stem Cell. 2013;12:737–747.
   PubMed Web of Science ®Google Scholar
• Handa K, Kiyohara S, Yamakawa T, et al. Bone loss caused by dopaminergic degeneration and levodopa treatment in Parkinson’s disease model mice. Sci Rep. 2019;9:13768.
   PubMed Web of Science ®Google Scholar
• Rittweger J, Frost HM, Schiessl H, et al. Muscle atrophy and bone loss after 90 days’ bed rest and the effects of flywheel resistive exercise and pamidronate: results from the LTBR study. Bone. 2005;36:1019–1029.
   PubMed Web of Science ®Google Scholar
• Verschueren S, Gielen E, O’Neill TW, et al. Sarcopenia and its relationship with bone mineral density in middle-aged and elderly European men. Osteoporos Int. 2013;24:87–98.
   PubMed Web of Science ®Google Scholar
• Johannesdottir F, Aspelund T, Siggeirsdottir K, et al. Midthigh cortical bone structural parameters, muscle mass and strength, and association with lower limb fractures in older men and women (AGES-reykjavik study). Calcif Tissue Int. 2012;90:354–364.
   PubMed Web of Science ®Google Scholar
• Peball M, Mahlknecht P, Werkmann M, et al. Prevalence and associated factors of sarcopenia and frailty in Parkinson’s disease: a cross-sectional study. Gerontology. 2019;65:216–228.
   PubMed Web of Science ®Google Scholar
• Olney RC. Regulation of bone mass by growth hormone. Med Pediatr Oncol. 2003;41:228–234.
   PubMedGoogle Scholar
• Isales CM, Zaidi M, Blair HC. ACTH is a novel regulator of bone mass. Ann N Y Acad Sci. 2010;1192:110–116.
   PubMed Web of Science ®Google Scholar
• Chiodini I, Scillitani A. Role of cortisol hypersecretion in the pathogenesis of osteoporosis. Recenti Prog Med. 2008;99:309–313.
   PubMedGoogle Scholar
• Bellomo G, Santambrogio L, Fiacconi M, et al. Plasma profiles of adrenocorticotropic hormone, cortisol, growth hormone and prolactin in patients with untreated Parkinson’s disease. J Neurol. 1991;238:19–22.
   PubMed Web of Science ®Google Scholar
• Lim SY, Fox SH, Lang AE. Overview of the extranigral aspects of Parkinson disease. Arch Neurol. 2009;66:167–172.
   PubMedGoogle Scholar
• Langston JW, Forno LS. The hypothalamus in Parkinson disease. Ann Neurol. 1978;3:129–133.
   PubMed Web of Science ®Google Scholar
• Conte-Devolx B, Pfister B, Viallet F, et al. The anterior pituitary endocrine function in Parkinson’s disease. Presse Med. 1987;16:566–568.
   PubMedGoogle Scholar
• Ding H, Dhima K, Lockhart KC, et al. Unrecognized vitamin D3 deficiency is common in Parkinson disease. Neurology. 2013;22:1531–1537.
   Google Scholar
• Evatt ML, Delong MR, Khazai N, et al. Prevalence of vitamin D insufficiency in patients with Parkinson disease and Alzheimer disease. Arch Neurol. 2008;65:1348–1352.
   PubMed Web of Science ®Google Scholar
• Wang L, Evatt ML, Maldonado LG, et al. Vitamin D from different sources is inversely associated with Parkinson disease. Mov Disord. 2015;30:560–566.
   PubMed Web of Science ®Google Scholar
• Sato Y, Kikuyama M, Oizumi K. High prevalence of vitamin D deficiency and reduced bone mass in Parkinson’s disease. Neurology. 1997;49:1273–1278.
   PubMed Web of Science ®Google Scholar
• Tan L, Wang Y, Zhou L, et al. Parkinson’s disease and risk of fracture: a meta-analysis of prospective cohort studies. PLoS One. 2014;9:e94379.
   PubMed Web of Science ®Google Scholar
• Goodwin V, Richards SH, Henley W, et al. An exercise intervention to prevent falls in people with Parkinson’s disease: a pragmatic randomised controlled trial. J Neurol Neurosurg Psychiatry. 2011;82:1232e1238.
   Web of Science ®Google Scholar
• Allen NE, Sherrington C, Paul SS, et al. Balance and falls in Parkinson’s disease: a meta-analysis of the effect of exercise and motor training. Mov Disord. 2011;26:1605–1615.
   PubMed Web of Science ®Google Scholar
• Silva de Lima AL, Smits T, Darweesh SKL, et al. Home-based monitoring of falls using wearable sensors in Parkinson’s disease. Mov Disord. 2020;35:109–115.
   PubMed Web of Science ®Google Scholar
• Woodford H, Walker R. Emergency hospital admissions in idiopathic Parkinson’s disease. Mov Disord. 2005;20:1104e8.
   Web of Science ®Google Scholar
• Otomune H, Mihara M, Hattori N, et al. Involvement of cortical dysfunction in frequent falls in patients with Parkinson’s disease. Parkinsonism Related Disord. 2019;64:169–174.
   PubMed Web of Science ®Google Scholar
• Braak H, Braak E. Pathoanatomy of Parkinson’s disease. J Neurol. 2000;247:II/3–II/10.
   PubMedGoogle Scholar
• Harris-Hayes M, Willis A, Klein S, et al. Relative Mortality in U.S. Medicare Beneficiaries with Parkinson Disease and Hip and Pelvic Fractures. J Bone Joint Surg Am. 2014;96(1–7):e27.
   PubMedGoogle Scholar
• Coomber R, Alshameeri Z, Masia AF, et al. Hip fractures and Parkinson’s disease: a case series. Injury. 2017;48:2730–2735.
   PubMed Web of Science ®Google Scholar
• Leisman G, Braun-Benjamin O, Melillo R. Cognitive-motor interactions of the basal ganglia in development. Front Syst Neurosci. 2014;8:16.
   PubMedGoogle Scholar
• Kucinskia A, Albin R, Lustig C, et al. Modeling falls in Parkinson’s disease: slow gait, freezing episodes and falls in rats with extensive striatal dopamine loss. Behav Brain Res. 2015;282:155–164.
   PubMed Web of Science ®Google Scholar
• Vetrano DL, Pisciotta MS, Laudisio A, et al. Sarcopenia in Parkinson disease: comparison of different criteria and association with disease severity. J Am Med Dir Assoc. 2018;19:523–527.
   PubMed Web of Science ®Google Scholar
• Sharir A, Stern T, Rot C, et al. Muscle force regulates bone shaping for optimal load-bearing capacity during embryogenesis. Development. 2011;138:3247–3259.
   PubMed Web of Science ®Google Scholar
• Bonewald LF, Kiel DP, Clemens TL, et al. Forum on bone and skeletal muscle interactions: summary of the proceedings of an ASBMR workshop. J Bone Miner Res. 2013;28:1857–1865.
   PubMed Web of Science ®Google Scholar
• Li M, Li C, Parkhouse WS. Age-related differences in the des IGF-I-mediated activation of Akt-1 and p70 S6K in mouse skeletal muscle. Mech Ageing Dev. 2003;124:771–778.
   PubMed Web of Science ®Google Scholar
• Liu JM, Zhao HY, Ning G, et al. IGF-1 as an early marker for low bone mass or osteoporosis in premenopausal and postmenopausal women. J Bone Miner Metab. 2008;26:159–164.
   PubMed Web of Science ®Google Scholar
• Prasad KN. Oxidative stress, pro-inflammatory cytokines, and antioxidants regulate expression levels of MicroRNAs in Parkinson’s disease. Curr Aging Sci. 2017;10:177–184.
   PubMedGoogle Scholar
• Godau J, Herfurth M, Kattner B, et al. Increased serum insulin-like growth factor 1 in early idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2010;81:536–538.
   PubMed Web of Science ®Google Scholar
• Godau J, Knauel K, Weber K, et al. Serum insulinlike growth factor 1 as possible marker for risk and early diagnosis of Parkinson disease. Arch Neurol. 2011;68:925–931.
   PubMedGoogle Scholar
• Fleming SM, Tetreault NA, Mulligan CK, et al. Olfactory deficits in mice overexpressing human wildtype alpha-synuclein. Eur J Neurosci. 2008;28:247–256.
   PubMed Web of Science ®Google Scholar
• Koprich JB, Johnston TH, Huot P, et al. Progressive neurodegeneration or endogenous compensation in an animal model of Parkinson’s disease produced by decreasing doses of alpha-synuclein. Plos One. 2011;6:e17698.
   PubMed Web of Science ®Google Scholar
• Crabtree DM, Zhang J. Genetically engineered mouse models of Parkinson’s disease. Brain Res Bull. 2012;88:13–32.
   PubMed Web of Science ®Google Scholar
• Emmer KL, Waxman EA, Covy JP, et al. E46K human alpha-synuclein transgenic mice develop Lewy-like and tau pathology associated with age-dependent, detrimental motor impairment. J Biol Chem. 2011;286:35104–35118.
   PubMed Web of Science ®Google Scholar
• Zimprich A, Müller-Myhsok B, Farrer M, et al. The PARK8 locus in autosomal dominant parkinsonism: confirmation of linkage and further delineation of the disease-containing interval. Am J Hum Genet. 2004;74:11–19.
   PubMed Web of Science ®Google Scholar
• Berwick DC, Javaheri B, Wetzel A, et al. Pathogenic LRRK2 variants are gain-of-function mutations that enhance LRRK2-mediated repression of β-catenin signaling. Mol Neurodegener. 2017;12:9.
   PubMed Web of Science ®Google Scholar
• Calabrese G, Mesner LD, Foley PL, et al. Network analysis implicates alpha-synuclein (snca) in the regulation of ovariectomy-induced bone loss. Sci Rep. 2016;6:29475.
   PubMed Web of Science ®Google Scholar
• Nakaia M, Fujitaa M, Waragaia M, et al. Expression of α-synuclein, a presynaptic protein implicated in Parkinson’s disease, in erythropoietic lineage. Biochem Biophys Res Commun. 2007;358:104–110.
   PubMed Web of Science ®Google Scholar
• Reid IR, Bolland MJ, Grey A. Effects of vitamin D supplements on bone mineral density: a systematic review and meta-analysis. Lancet. 2014;383:146–155.
   PubMed Web of Science ®Google Scholar
• Zhu K, Austin N, Devine A, et al. A randomized controlled trial of the effects of vitamin d on muscle strength and mobility in older women with vitamin d insufficiency. J Am Geriatr Soc. 2010;58:2063–2068.
   PubMed Web of Science ®Google Scholar
• Dhesi JK, Jackson SH, Bearne LM, et al. Vitamin D supplementation improves neuromuscular function in older people who fall. Age Ageing. 2004;33:589–595.
   PubMed Web of Science ®Google Scholar
• Murad MH, Elamin KB, Abu Elnour NO, et al. The effect of vitamin d on falls: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2011;10:2997–3006.
   Google Scholar
• Bolland MJ, Grey A, Avenell A. Effects of vitamin D supplementation on musculoskeletal health: a systematic review, meta-analysis, and trial sequential analysis. Lancet Diabetes Endocrinol. 2018;6:847–858.
   PubMed Web of Science ®Google Scholar
• Burt LA, Billington EO, Rose MS, et al. Effect of high-dose vitamin d supplementation on volumetric bone density and bone strength: a Randomized Clinical Trial. JAMA. 2019;27:736–745.
   Google Scholar
• Keen R. Osteoporosis: strategies for prevention and management. Best Pract Res Clin Rheumatol. 2007;21:109–122.
   PubMed Web of Science ®Google Scholar
• MacLean C, Newberry S, Maglione M, et al. Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med. 2008;148:197–213.
   PubMed Web of Science ®Google Scholar
• Reid I, Brown JP, Burckhardt P, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med. 2002;346:653–661.
   PubMed Web of Science ®Google Scholar
• Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356:1809–1822.
   PubMed Web of Science ®Google Scholar
• Eastell R, Christiansen C, Grauer A, et al. Effects of denosumab on bone turnover markers in postmenopausal osteoporosis. J Bone Miner Res. 2011;26:530–537.
   PubMed Web of Science ®Google Scholar
• Lindsay R, Nieves J, Formica C, et al. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet. 1997;350:550–555.
   PubMed Web of Science ®Google Scholar
• Dobnig H, Sipos A, Jiang Y, et al. Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy. J Clin Endocrinol Metab. 2005;90:3970–3977.
   PubMed Web of Science ®Google Scholar
• Fontalis A, Kenanidis E, Kotronias RA, et al. Current and emerging osteoporosis pharmacotherapy for women: state of the art therapies for preventing bone loss. Expert Opin Pharmacother. 2019;20:1123–1134.
   PubMed Web of Science ®Google Scholar
• Miller PD, Hattersley G, Riis BJ, et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. JAMA. 2016;316:722–733.
   PubMed Web of Science ®Google Scholar
• Bhasin S, Gill TM, Reuben DB, et al. Strategies to reduce injuries and develop confidence in elders (stride): a cluster-randomized pragmatic trial of a multifactorial fall injury prevention strategy: design and methods. J Gerontol A Biol Sci Med Sci. 2018;73:1053–1061.
   PubMed Web of Science ®Google Scholar
• Cummings SR, Eastell R. Risk and prevention of fracture in patients with major medical illnesses: a mini-review. J Bone Miner Res. 2016;31:2069–2072.
   PubMed Web of Science ®Google Scholar
• Athauda D, Maclagan K, Skene SS, et al. Exenatide once weekly versus placebo in Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390:1664–1675.
   PubMed Web of Science ®Google Scholar